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Abstract
Background: Diabetes is related with increased cancer mortality across multiple cancer types. Its role in lung cancer
mortality is still unclear. We aim to determine the prognostic value of fasting plasma glucose (FPG) and diabetes mellitus
in patients with locally advanced non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy.
Methods: One-hundred seventy patients with stage III NSCLC received definitive concurrent chemoradiotherapy from
2010 to 2014. Clinico-pathological data and clinical outcome was retrospectively registered. Fifty-six patients (33%), met
criteria for type 2 diabetes mellitus (T2DM) at baseline. The prognostic value of FPG and other clinical variables was
assessed. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and
Cox proportional models and log-rank test were used.
Results: With a median follow-up of 36months, median PFS was 8.0 months and median OS was 15.0 months in
patients with FPG ≥7mmol/L compared to 20months (HR 1.13; 95% CI 1.07–1.19, p < 0.001) and 31months (HR 1.09;
95% CI 1.04–1.15; p < 0.001) respectively, for patients with FPG < 7mmol/L. In the multivariate analysis of the entire
cohort adjusted by platinum compound and comorbidities, high levels of FPG as a continuous variable (HR 1.14; 95%
CI 1.07–1.21; p < 0.001), the presence of comorbidity (HR 1.72; 95% CI 1.12–2.63; p = 0.012), and treatment with
carboplatin (HR 1.95; 95% CI 1.26–2.99; p = 0.002) were independent predictors for shorter OS. In additional multivariate
models considering non-diabetic patients as a reference group, diabetic patients with poor metabolic control
(HbA1c > 8.5%) (HR 4.53; 95% CI 2.21–9.30; p < 0.001) and those receiving insulin (HR 3.22; 95% CI 1.90–5.46 p < 0.001)
had significantly independent worse OS.
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Conclusion: Baseline FPG level is an independent predictor of survival in our cohort of patients with locally advanced
NSCLC treated with concurrent chemoradiotherapy. Studies in larger cohorts of patients are warranted to confirm this
relevant association.
Keywords: Locally advanced unresectable non-small cell lung cancer, Concurrent chemoradiotherapy, Hyperglycemia,
Type 2 diabetes mellitus, Comorbidities
Key message
In this study, we determine the prognostic value of fast-
ing plasma glucose (FPG) and Type 2 Diabetes Mellitus
(T2DM) in patients with stage III non-small cell lung
cancer treated with concurrent chemoradiotherapy. High
FPG at baseline predicts worse clinical outcome inde-
pendently of other clinical variables. Metabolic control
and antidiabetic treatment might also influence outcome
in diabetic patients.
Background
Diabetes has been associated with an increased inci-
dence and mortality in many types of cancer [1–3]. Dia-
betes may influence cancer progression and outcome by
several mechanisms, including hyperinsulinemia, hyper-
glycemia, or chronic inflammation. In addition, type 2
diabetes mellitus (T2DM) is a risk factor for other
non-neoplastic causes of death in cancer patients [4].
The role of diabetes in the prognosis of patients with
lung cancer has not been well established [5]. Some clin-
ical and epidemiologic studies showed that pre-existing
diabetes has a negative impact on lung cancer mortality
[5–7]. A worse prognosis in diabetic patients with lung
cancer has been mainly seen in women [6], patients with
non-small cell lung cancer (NSCLC) and in those pa-
tients treated with surgical resection [5]. However, these
observational studies have methodological limitations
such as the absence of screening for T2DM [2], the lack
of cause-specific death reporting and the heterogeneity
of tumor stage at cancer diagnosis [7].
The use of baseline glycemia as a continuous variable
could avoid the problem of T2DM underdiagnosis. In
fact, fasting plasma glucose (FPG) level has been inde-
pendently associated with an increased risk of mortality
in a cohort of patients with newly diagnosed NSCLC [7].
In addition, The Emerging Risk Factors Collaboration
Study analyzed the potential independent associations
between diabetes or hyperglycemia with the risk of death
from cancer. This study showed an association between
high FPG levels (exceeding 100 mg per deciliter or 5.6
mmol per liter)and cancer specific mortality [8].
The influence of antidiabetic therapy on cancer inci-
dence and mortality has been the subject of many obser-
vational epidemiologic studies in large populations [9, 10].
These studies suggest that metformin is associated with a
decrease in cancer mortality, while data regarding other
antidiabetic medications are conflicting [10, 11]. The
Danish Cancer Registry provided evidence that among
cancer patients with pre-existing diabetes, mortality rates
were higher on patients receiving insulin [12].
The purpose of our study is to determine the influence
of T2DM and FPG levels on survival in a cohort of pa-
tients with unresectable locally advanced NSCLC treated
with concurrent chemoradiotherapy. The influence on
overall survival (OS) of antidiabetic treatments and gly-
cemic control among T2DM patients were also evalu-
ated as secondary endpoints.
Methods
Study population
Eligible patients for this study had histological or cyto-
logical confirmation of NSCLC, locally advanced disease
based on clinical assessments: cardiopulmonary function,
contrast thoracic computed tomography (CT) scan and
positron-emitted tomography-CT (PET-CT) scan, mag-
netic resonance imaging (MRI) of the brain and selective
mediastinal staging with endobronquial ultrasonography
and/or endoscopic (EBUS/END) ultrasonography; had
been considered candidates for non-surgical cancer treat-
ment by the Multidisciplinary Thoracic Oncology Board
and had received definitive concurrent chemoradiation.
From January 2010 to December 2014 the medical records
of 170 consecutive patients from our institution fulfilling
all those criteria were reviewed. We collected the follow-
ing data: age, sex, smoking history, weight loss during the
6months previous to NSCLC diagnosis, Eastern Coopera-
tive Oncology Group performance status (ECOG PS), hist-
ology and clinical stage according to the 7th edition of
TNM classification [13], chemotherapy regimen, total
dose of radiotherapy and treatment-related toxicity. We
did not use any established comorbidity scale such as
Charlson Comorbidity Index or the Simplified Comorbid-
ity Score due to the strong influence of T2DM on those
scales [14]. Presence of relevant comorbidities was regis-
tered (renal insufficiency, chronic obstructive pulmonary
disease (COPD) cardiovascular disease and chronic
hepatic disease). Thoracic radiotherapy was administered
up to a total dose of 60 to70 Gy (1.8–2 Gy per fraction
over 6–7 weeks of treatment). Chemotherapy regimens,
starting the first day of radiotherapy, were based on
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cisplatin or carboplatin combined with etoposide, vinorel-
bine, pemetrexed or paclitaxel. None of the patients re-
ceived consolidation with durvalumab after completing
chemoradiotherapy. Patients were followed-up until June
2017. This study was approved by the Institutional Review
Board and recorded data were anonymized for analysis.
Diabetes evaluation and treatment
Patients had been assessed before cancer treatment by a
nutritionist plus/minus an endocrinologist both working
as a team at our Institution. Patients were classified as
having T2DM if the diagnosis was in their medical rec-
ord, if they were on antidiabetic drugs or if they met the
diagnostic criteria for diabetes according to the Ameri-
can Diabetes Association (ADA) Criteria from 2016 [15].
FPG measured less than 1 week before starting cancer
treatment was considered the baseline glycemia. Hyper-
glycemia was defined as FPG ≥ 7 mmol/L (≥126 mg/dL).
Last available glycated hemoglobin (HbA1c) was
recorded for diabetic patients with a maximum of 6
months before starting oncologic treatment. T2DM
patients were classified into three groups of glycemic
control: good (HbA1c ≤ 7%), moderate (HbA1c 7.1–
8.5%) and poor (HbA1c > 8.5%) [9]. Those antidiabetic
drugs that the patient was receiving when oncologic
treatment was started were collected.
Statistical analysis
Chi square test for categorical and T- Student test for
continuous variables were used to compare the charac-
teristics of T2DM and non-diabetic patients. Overall sur-
vival (OS) was defined as the time between lung cancer
diagnosis and death, progression free survival (PFS) was
defined as the time between histological diagnosis and
radiological progression of the disease or death, which-
ever came first. Patients with no evaluable radiological
images were censored. Kaplan–Meier method was used
to estimate OS and PFS. The Cox proportional hazard
regression model and the log-rank test were used to
assess differences among prognostic factors. Multivariate
survival analysis was performed using Cox Regression
with the Forward Step model. A two-tailed p-value of
less than 0.05 was considered statistically significant. All
analyses were carried out using the SPSS 22.0 statistical
software (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
In this cohort of 170 patients, 56 (33%) met T2DM cri-
teria. There were no patients with type 1 diabetes melli-
tus. Baseline characteristics, including gender, smoking
history, ECOG PS, comorbidity and stage were similar in
patients with T2DM and in non-diabetic patients
(Table 1). Diabetic patients were more likely to have
squamous tumors (51.8% vs 37.7%, p = 0.004) and to re-
ceive carboplatin regimens (51.7%) compared with
non-diabetic patients (32.5%) (p = 0.019). Median num-
ber of cycles of chemotherapy and the total dose of radi-
ation therapy received were similar in T2DM and
nondiabetic patients. There were no statistically signifi-
cant differences in comorbidities between T2DM and
non-diabetic patients, with the exception of cardiovascu-
lar disease that was more common in diabetic patients
(33.3% vs 13.8%, p = 0.003).
Among T2DM patients, 39 (69.6%) were receiving an-
tidiabetic medication at lung cancer diagnosis. Twenty
patients were receiving metformin alone or in combin-
ation with other oral hypoglycemic agents and 19 were
on insulin treatment alone or with oral hypoglycemic
drugs. Relevant baseline nutritional characteristics are
shown in Additional file 1: Table S1. Overweight and
obesity were more likely in T2DM patients. No statisti-
cally significant differences were observed in terms of
type of chemotherapy received concurrently with thor-
acic radiotherapy as shown in Additional file 1: Table S2.
Overall survival
After a median follow-up of 36 months, 47 patients
(27.6%) were alive. Median PFS was 12months (95% CI
9–15) and median OS was 26months (95% CI 20–32)
for the whole cohort. Major causes of death were tumor
progression (80%), treatment-related adverse events
(7.8%), cardiovascular disease (7%), other causes (3.5%)
and second tumors (1.7%). There were no significant dif-
ferences in causes of death between diabetic and
non-diabetic patients (p = 0.402). There were no signifi-
cant differences in the pattern of tumor progression
among diabetic and non-diabetic patients (p = 0.274).
Univariate survival analysis according to T2DM related
variables
Median OS was significantly shorter in patients with
FPG ≥ 7 mmol/L (15 months) compared to patients with
FPG < 7mmol/L (31 months, HR 1.09; 95% CI 1.04–
1.15; p < 0.001; Fig. 1a). Median PFS was also signifi-
cantly shorter in patients with high FPG compared to
patients with FPG < 7mmol/L (8 vs 20 months; HR 1.13;
95% CI 1.07–1.19; p < 0.001; Fig. 1b).
Median OS was significantly inferior in T2DM patients
(17months) compared to non-diabetic patients (32months,
HR 1.72; 95% CI 1.17–2.54; p = 0.005; Fig. 2a). Median PFS
was significantly inferior in T2DM as well (10 vs 16
months; HR 1.68; 95% CI 1.14–2.47; p = 0.003; Fig. 2b).
HbA1c levels were available in 45 patients with
T2DM. Significant differences in median OS were ob-
served between patients with good (28 months; n = 21)
and moderate metabolic control (20months; n = 14) com-
pared to those with poor metabolic control (8months; n =
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10) (HR 0.37; 95% CI 0.16–0.89, p = 0.022; HR 0.37; 95% CI
0.15–0.92; p = 0.033, respectively; Fig. 3a). No statistically
significant differences were found in OS between T2DM
patients with good metabolic control and non-diabetic pa-
tients (28 vs 31months; p = 0.34). Interestingly, differences
in OS were observed according to antidiabetic treatment.
Patients treated with insulin had significantly shorter me-
dian OS compared to those receiving metformin or not
treated with antidiabetic agents (11m vs 24m vs 21m, re-
spectively; p = 0.001; Fig. 3b).
Patients with poor metabolic control (HbA1c > 8.5%)
did not have significantly higher presence of comorbidity
(Additional file 1: Table S3). Patients receiving insulin
were more likely to have poor metabolic control (p =
0.045, Additional file 1: Table S4).
Multivariate analysis
We performed a multivariate Cox regression analysis in-
cluding all patients in the study. We introduced prog-
nostic factors previously described in NSCLC patients
(age, histology, smoking status, ECOG PS, platinum
treatment, comorbidity, BMI, weight loss before treat-
ment, nodal status). Pre-treatment FPG level (HR 1.13;
95% CI 1.06–1.21; p < 0.001) was an independent prog-
nostic factor, whereas T2DM diagnosis was not (Add-
itional file 1: Table S5). The type of platinum treatment
(HR 1.66; 95%CI 1.12–2.45; p = 0.011) and the presence
of comorbidity (HR 1.51; 95% CI 1.02–2.23; p = 0.039)
were independent prognostic factors for OS as well.
However, weight loss was not associated with overall
survival in the multivariate analysis.
Table 1 Baseline characteristics
T2DM (n = 56) Non T2DM (n = 114) All(n = 170) p-value
Age,median (range) 66 (49–81) 63 (37–87) 64 (37–87) 0.094
Gender,n (%)
Male 51 (91.1%) 97 (85.1%) 148 (87%)
Female 5 (8.9%) 17 (14.9%) 22 (13%) 0.337
Smoking history, n (%)
Current 27 (48.2%) 57 (50%) 84 (49.4%)
Former 24 (42.8%) 51 (44.7%) 75 (44.1%)
Never 3 (5.4%) 4 (3.5%) 7 (4.1%)
Unknown 2 (3.6%) 2 (1.8%) 4 (2.4%) 0.837
ECOG PS, n (%)
PS 0–1 53 (94.6%) 102 (90.3%) 155 (91.1%)
PS 2 3 (5.4%) 12 (9.7%) 15 (8.9%) 0.331
Histology n (%)
Adenocarcinoma 9 (16%) 48 (42.1%) 57 (33.5%)
Squamous 29 (51.8%) 43 (37.7%) 72 (42.3%)
NOS 18 (32.2%) 23 (20.2%) 41 (24.2%) 0.003
Stage, n (%)
IIIA 31 (55.3%) 54 (47.4%) 85 (50%)
IIIB 23 (41.1%) 58 (50.9%) 81 (47.6%) 0.321
Mean baseline glycemia (mmol/L) 9.22 ± 6.35 5.6 ± 1.2 6.75 ± 4.70 < 0.001
Comorbidities
Any 34 (60.7%) 69 (60.5%) 103 (60.6%) 0.981
Renal Insufficiency 5 (8.9%) 7 (6.1%) 12 (7.1%) 0.445
COPD 21 (37.5%) 50 (44%) 71 (41.8%) 0.604
Cardiovascular
Hepatopathy
18 (32.1%)
2 (3.6%)
16 (14%)
0 (0%)
34 (20%)
2 (1.2%)
0.003
1.000
Platinum doublet, n (%)
Cisplatin 27 (48.2%) 77 (67.5%) 104 (61.2%)
Carboplatin 29 (51.7%) 37 (32.5%) 66 (38.8%) 0.019
Total dose of RDT between 60-70Gys 54 (96.4%) 106 (93%) 160 (94%) 0.716
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, COPD chronic obstructive pulmonary disease, NOS not otherwise specified, RDT
radiotherapy, T2DM type 2 diabetes mellitus
Bergamino et al. BMC Cancer          (2019) 19:165 Page 4 of 9
We constructed two additional models for metabolic
control of diabetes and insulin treatment, with
non-diabetic patients as the reference group. In the
multivariate analysis, poor metabolic control (HbA1c >
8.5%) (HR 4.53; 95% CI 2.21–9.30; p < 0.001) and insulin
treatment (HR 3.22; 95% CI 1.91–5.46; p < 0.001) were
independent prognostic factors when adjusted for the
above-mentioned variables (Table 2).
Discussion
In this homogeneous cohort of consecutive patients with
unresectable locally advanced NSCLC, both pre-treatment
FPG level and diagnosis of T2DM were predictors of over-
all survival. However, only FPG level retained its signifi-
cance in the multivariate analysis. Interestingly, PFS, a
cancer-related outcome, was significantly shorter for pa-
tients with high FPG, suggesting a direct relationship be-
tween both variables.
Several mechanisms may explain the negative effect of
hyperglycemia and diabetes on lung cancer related
outcome. Hyperinsulinemia and metabolic rewiring of
cancer cells are potential factors contributing to the
development and progression of cancer. According to
Warburg’s hypothesis, the hyperglycemic environment
may accelerate the proliferation of cancer cells, as they
can obtain essential metabolites and energy mainly from
fermentation of glucose, even in aerobic conditions [16,
17]. Data from patients and mouse models indicates that
lung tumors are dependent on glucose metabolism, and
increased expression of glycolytic enzymes correlate with
A B
Fig. 1 Kaplan Meier curves for overall survival (a) and progression-free survival (b) according to pre-treatment Fasting plasma glucose (FPG) in the
whole cohort (n = 170). Patients with FPG ≥7 mmol/L had significantly shorter median OS and PFS compared with patients with FPG < 7mmol/L.
Abbreviations: Overall Survival (OS), Progression Free Survival (PFS)
A B
Fig. 2 Kaplan Meier curves for overall survival (a) and progression-free survival (b) according to diagnosis of type 2 diabetes mellitus (T2DM) in
the whole cohort (n = 170). Patients with T2DM diagnosis had significantly shorter median OS and PFS compared with patients without T2DM
history. Abbreviations: Overall Survival (OS), Progression Free Survival (PFS)
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poor prognosis. In our study, squamous cell carcinoma
histology was more probable in diabetic patients. A
recent case-control study showed an increased risk of
lung cancer associated with glycemic load and dietary
glycemic index, as a marker of carbohydrate intake and
postprandial glucose response. The risk was greater for
the development of squamous cell carcinoma [18]. In
another study, squamous cell lung carcinoma was associ-
ated with enhanced glucose uptake and exhibited higher
glycolytic dependency than adenocarcinoma [19].
Han et al. found that high glucose levels can promote
cancer proliferation via the induction of epidermal
growth factor (EGF) expression and transactivation of
EGF receptor [20]. Hyperglycemia has also shown to
decrease the antiproliferative effect of chemotherapy in
preclinical models, but the results are inconsistent and
have not been proven in clinical trials [21]. Some retro-
spective series have also shown a negative impact on
survival of elevated blood glucose levels during radiation
therapy in glioblastomas. This detrimental effect may be
explained by the metabolic impact on tumor microenvir-
onment, but also by the induction of hypoxia that
promotes resistance to radiotherapy [22, 23].
The association of high FPG with outcome in lung
cancer patients in a clinical setting has already been
reported. In an unselected cohort of 342 patients with
newly diagnosed NSCLC, Luo et al. observed that
patients with FPG levels ≥7.0 mmol/L (≥ 126 mg/dl) had
shorter survival outcome independently of other prog-
nostic factors [7]. In another retrospective study, 159
patients with locally advanced NSCLC were treated with
radical chemoradiotherapy and those patients who had a
previous diagnosis of diabetes or with FPG ≥ 7.0 mmol/L
had a significantly shorter survival independently of
other prognostic factors [24]. In this study, FPG level
was not studied in a separate model in the multivariate
analysis, and the value of this parameter at baseline as a
continuous variable was not clarified. By contrast, in our
study, previous diagnosis of T2DM lost its statistical sig-
nificance in the multivariate analysis, whereas FPG
maintained a strong effect.
To evaluate the influence of metabolic control of dia-
betes on cancer outcome, we explored the association of
HbA1c (as a dichotomous variable) with the prognosis
of lung cancer. We observed that diabetic patients with
the poorest glycemic control (HbA1c > 8.5%) had the
shortest survival, and that diabetic patients with good
metabolic control (HbA1c < 7%) had a similar OS than
non-diabetic patients. Moreover in a multivariate model
poor metabolic control was independently related to
prognosis. These findings underline the potential benefit
of achieving good metabolic control to improve cancer
outcome in diabetic patients [25].
The influence of antidiabetic treatment on cancer prog-
nosis is still controversial. Metformin is an antidiabetic
drug that suppresses hepatic neoglucogenesis and im-
proves insulin sensitivity. Preclinical data have shown that
metformin has direct and indirect potent antitumor ef-
fects in several cancers, including lung. However the con-
centration of metformin used in these studies is about one
thousand times higher than that achieved in the blood in
humans [26]. Some epidemiological studies in lung cancer
have shown better outcomes in metformin-treated pa-
tients compared to diabetic patients receiving other
A B
Fig. 3 Kaplan Meier curves for OS in type 2 T2DM and non-diabetic patients according to metabolic control based on HbA1 (a) and type of
anti-diabetic treatment (b). Patients with poor metabolic control (HbA1c > 8.5%) had shorter median OS as compared with the rest of diabetic
patients and nondiabetic patients. Patient receiving insulin had also worse OS compared with the rest of diabetic patients. Abbreviations: Type 2
Diabetes Mellitus (T2DM), Overall survival (OS), Glycated Haemoglobin (HbA1c)
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antidiabetic drugs [10, 11, 27]. Ahmed I et al., in a study
with 166 patients, did not find any differences in survival
between diabetic and non-diabetic patients except for be-
ing on metformin treatment or not [28]. More than 200
clinical trials [10] are ongoing aiming to determine
whether the preclinical anticancer effect of metformin
translates into clinical benefit. The Danish Cancer Registry
showed a higher mortality among patients treated with
insulin [12]. In line with those reports, we observed that
patients treated with insulin (± oral hypoglycemic drugs)
had a worse prognosis than patients on metformin treat-
ment (without insulin) or those that did not receive any
antidiabetic treatment.
A common concern when studying the relationship
between diabetes and cancer prognosis is the higher
prevalence of comorbidities in diabetic patients and the
existence of competing causes of death. We did not
identify significant differences in the cause of death be-
tween diabetic and non-diabetic patients. Although pa-
tients with T2DM had higher prevalence of overweight,
body mass index (BMI) was not a significant prognostic
factor in our study. We also collected basic malnutrition
measures as weight loss before treatment and baseline
albumin level as known prognostic factors. However,
none of these factors was different between the T2DM
and the non-diabetic patients or achieved significance in
the survival analysis. Another prominent issue is that the
presence of T2DM could lead to a less intensive antican-
cer treatment. Although diabetic patients were more
likely treated with carboplatin than cisplatin and, carbo-
platin treatment was associated with unfavorable overall
survival in the multivariate analysis, baseline FPG, meta-
bolic control and insulin treatment remained independ-
ent prognostic factors after adjusting by platinum
treatment.
The major limitation of our study is the relatively low
sample size, which could lead to residual confounding as
we do not have enough power to identify some
well-known risk factors and compromises the analysis of
subsets of patients. Another weakness is the retrospect-
ive nature of the study, which means that there was not
a dedicated pre-planned design of patient management
and data collection. The strength of our study is the
uniform clinical practice on cancer and diabetic manage-
ment at a single institution. The most relevant finding is
that baseline FPG level is a strong predictor of survival
in a set of consecutive patients treated with definitive
chemoradiotherapy. Our results on the prognostic value
of metabolic control and antidiabetic treatment have po-
tential clinical implications and are consistent with what
has been reported in the literature, but should be
regarded with caution due to the limitations of the
study.
Conclusions
Our data support that baseline FPG level may impact on
the outcome of patients with locally advanced NSCLC.
The validation of this association in a large cohort of
locally advanced NSCLC patients is warranted. In the
complex relationship between cancer and diabetes our
Table 2 Multivariate analysis for Overall Survival for selected
prognostic factors in NSCLC. A model was built for each
variable of interest. All the variables listed at the upper file were
included in the multivariabte Cox model, but the hazard ratios
are shown only for those covariates that remained statistically
significant during the forward stepwise analysis
Model 1
Covariates Age, Histology, Smoking status, ECOG PS, platinum
treatment, comorbidity, BMI, weight loss, nodal status, pre-
treatment fasting plasma glucose (FPG).
Variables
in the
equation
Parameter Level Hazard
Ratio
95%
Confidence
Interval
p-value
Pre-
treatment
FPG
Continuous 1.134 1.066–1.207 < 0.001
Platinum
treatment
Carboplatin
vs cisplatin
1.657 1.121–2.451 0.011
Comorbidity Yes vs No 1.508 1.020–2.229 0.039
Model 2
Covariates Age, Histology, Smoking status, ECOG PS, platinum
treatment, comorbidity, BMI, weight loss, nodal status,
metabolic control groups.
Variables
in the
equation
Parameter Level Hazard
Ratio
95%
Confidence
Interval
p-value
Metabolic
control
groups
No diabetes
(reference
group)
HbA1c ≤7 1.342 0.752–2.395 0.319
HbA1c
7.1–8.5
0.830 0.400–1.719 0.616
HbA1c > 8.5 4.534 2.210–9.301 < 0.001
Platinum
treatment
Carboplatin
vs cisplatin
1.946 1.264–2.996 0.002
Comorbidity Yes vs No 1.720 1.125–2.632 0.012
Model 3
Covariates Age, Histology, Smoking status, ECOG PS, platinum
treatment, comorbidity, BMI, weight loss, nodal status,
insulin treatment.
Variables
in the
equation
Parameter Level Hazard
Ratio
95%
Confidence
Interval
p-value
Insulin
treatment
Yes vs No 3.225 1.906–5.456 < 0.001
Platinum
treatment
Carboplatin
vs cisplatin
1.574 1.075–2.306 0.020
Abbreviations: BMI body mass index, ECOG PS Eastern Cooperative Oncology
Group performance status, FPG fasting plasma glucose, HbA1c
glycated haemoglobin
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results suggest that metabolic control and treatment of
diabetes might influence cancer-related outcomes. Pro-
spective research in the field of diabetic control and
management in lung cancer patients is necessary to pro-
vide insight into these issues.
Additional file
Additional file 1: Table S1. Nutritional baseline characteristics in T2DM
and non-diabetic patients. Table S2.Chemotherapy regimens given con-
currently with thoracic radiotherapy in T2DM and non-diabetic patients.
Table S3.Presence of comorbidity according to metabolic control in
T2DM patients (n = 45). Table S4.Metabolic control based on HbA1c ac-
cording to antidiabetic treatment (n = 45). Table S5.Multivariate analysis
for Overall Survival for selected prognostic factors in NSCLC including
T2DM as covariate. (DOCX 20 kb)
Abbreviations
ADA: American Diabetes Association; BMI: Body Mass Index; COPD: Chronic
obstructive pulmonary disease; CT: Computed tomography; EBUS/
EUS: Endobronchial/endoscopic ultrasound; ECOG PS: Eastern Cooperative
Oncology Group performance status; FPG: Fasting plasma glucose;
HbA1c: Glycated hemoglobin; NSCLC: Locally advanced non-small cell lung
cancer; OS: Overall survival; PET-CT: Positron emission tomography-CT;
PFS: Progression-free survival; T2DM: Type 2 Diabetes Mellitus
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